AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/09/20

- Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis - - DDI study demonstrates no clinically meaningful interaction between voclosporin and MMF, supporting differenti...

Gainers: Inspire Medical Systems (INSP) +24%, GW Pharmaceuticals (GWPH) +15%, Aptevo Therapeutics (APVO) +14%, Galera Therapeutics (GRTX) +11%, DBV Technologies (DBVT) +10%.Losers: Esperion Therapeutics (ESPR) -15%, Aurinia Pharmaceuticals (AUPH)&#...

Apartment Investment and Management (AIV) -23%.SolarEdge Technologies (SEDG) -18% on Q3 earnings release.Pacific Biosciences of California (PACB) -10% on Q3 earnings release.Aurinia Pharmaceuticals (AUPH) -9% on suspending voclosporin program as Phase 2/3 study f...

Aurinia Pharmaceuticals (AUPH) down 10% after-hours after announcing topline data from the Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution ((VOS)) for the potential treatment of dry eye syndrome ((DES)).The trial did not achieve statistical significance on...

Gainers: [[ANET]] +23.9%. [[JAKK]] +22.3%. [[MED]] +11.5%. [[INSP]] +10.1%. [[CDLX]] +9.5%.Losers: [[SEDG]] -19.1%. [[AUPH]] -10.3%. [[PACB]] -6.8%. [[IPI]] -5.8%. [[BRKR]] -4.6%. For further details see: ANET, JAKK, PACB and SEDG among after-hours movers

- The trial did not achieve statistical significance on the primary endpoint of ≥ 10mm improvement in Schirmer Tear Test (STT) at 4 weeks – - Company to suspend development program for voclosporin ophthalmic solution (VOS) - - Aurinia to host conference c...

Aurinia Pharmaceuticals (AUPH) has announced the funding and initiation of an open-label exploratory trial evaluating its lead drug, voclosporin in kidney transplant recipients with COVID-19.This 56-day open-label investigator initiated trial is designed to evaluate the antiviral effects...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the funding and initiation of an open-label explor...

Aurinia Pharmaceuticals (AUPH) has announced that integrated efficacy and pharmacokinetic data from AURA-LV and AURORA pivotal trials of voclosporin in lupus nephritis ((LN)) were presented at the American Society of Nephrology Kidney Week.Integrated data from 534 patients from both the trial...

- Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – - Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need for therapeutic d...